Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans L Tillmann

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
Antiviral Therapy|December 13, 2018
Hindsight is 20/20 - the importance of knowing! Know your patients' HBV statusSirish Sanaka, Hans L Tillmann
Seminars in Hematology|July 13, 2010
Use of thrombopoietic agents for the thrombocytopenia of liver diseaseHans L Tillmann, John G McHutchison
Gastroenterology|December 3, 2014
Improved prediction of the need for liver transplantation in patients with drug-induced liver injury?Hans L Tillmann, Don C Rockey
Current Opinion in Gastroenterology|March 25, 2020
Signatures in drug-induced liver injuryHans L Tillmann, Don C Rockey
The New England Journal of Medicine|April 4, 2008
Telbivudine versus lamivudine in patients with chronic hepatitis BHans L Tillmann, John G McHutchison
Liver International : Official Journal of the International Association for the Study of the Liver|November 19, 2011
IL28B: relevance extended to hepatitis B virus or limited to interferon-based therapies in hepatitis C virus?Hans L Tillmann, Ming-Whei Yu
Digestion|November 3, 2010
Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of GermanySimon Lobstein, Renaldo Faber, Hans L Tillmann
Alimentary Pharmacology & Therapeutics|January 22, 2026
Letter: Using Anti-HBs Titers to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours-Authors' ReplyHans L Tillmann, Shiva Poola, MaryKate Kratzer
Digestion|November 22, 2008
Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterionHans L Tillmann, Alexander J V Thompson
Antiviral Therapy|May 29, 2008
Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidenceJohannes Wiegand, Dirk Hasenclever, Hans L Tillmann
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
Antiviral Therapy|December 13, 2018
Hindsight is 20/20 - the importance of knowing! Know your patients' HBV statusSirish Sanaka, Hans L Tillmann
Seminars in Hematology|July 13, 2010
Use of thrombopoietic agents for the thrombocytopenia of liver diseaseHans L Tillmann, John G McHutchison
Gastroenterology|December 3, 2014
Improved prediction of the need for liver transplantation in patients with drug-induced liver injury?Hans L Tillmann, Don C Rockey
Current Opinion in Gastroenterology|March 25, 2020
Signatures in drug-induced liver injuryHans L Tillmann, Don C Rockey
The New England Journal of Medicine|April 4, 2008
Telbivudine versus lamivudine in patients with chronic hepatitis BHans L Tillmann, John G McHutchison
Liver International : Official Journal of the International Association for the Study of the Liver|November 19, 2011
IL28B: relevance extended to hepatitis B virus or limited to interferon-based therapies in hepatitis C virus?Hans L Tillmann, Ming-Whei Yu
Digestion|November 3, 2010
Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of GermanySimon Lobstein, Renaldo Faber, Hans L Tillmann
Alimentary Pharmacology & Therapeutics|January 22, 2026
Letter: Using Anti-HBs Titers to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours-Authors' ReplyHans L Tillmann, Shiva Poola, MaryKate Kratzer
Digestion|November 22, 2008
Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterionHans L Tillmann, Alexander J V Thompson
Antiviral Therapy|May 29, 2008
Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidenceJohannes Wiegand, Dirk Hasenclever, Hans L Tillmann
Pageof 13